The progress of urine DNA methylation detection in non-invasive diagnosis of bladder cancer
10.3760/cma.j.cn112330-20200924-00020
- VernacularTitle:尿液DNA甲基化检测在膀胱癌无创诊断中的研究进展
- Author:
Tao XU
1
;
Caipeng QIN
Author Information
1. 北京大学人民医院泌尿外科，北京 100044
- From:
Chinese Journal of Urology
2020;41(10):721-723
- CountryChina
- Language:Chinese
-
Abstract:
At present, the diagnosis and recurrence monitoring of bladder cancer are mainly achieved by invasive cystoscopy, while non-invasive urine diagnostic techniques such as exfoliative cytology, fluorescence in situ hybridization (FISH) and bladder tumor antigen (BTA) are not highly sensitive and/or specific, and are prone to missed diagnosis or misdiagnosis. Therefore, the development of high-sensitivity non-invasive diagnostic techniques for bladder cancer can improve the current status of diagnosis and treatment while reducing the suffering of patients. Recently, the internationally renowned journal "Journal of Clinical Investigation" published the research results of Chinese scholars, Jian Huang/Tianxin Lin and their team who have developed a non-invasive technique for bladder cancer based on urine DNA methylation, which is significantly more sensitive than that clinically common-used technology such as exfoliative cytology and FISH. In particular, it has shown significant advantages in the diagnosis of early, minimal, residual or recurrent bladder cancer, which significantly improves the diagnosis rate of bladder cancer. This technique is expected to reduce the use of cystoscopy and provides new methods for precise diagnosis and treatment of bladder cancer. This article elaborates the current status of non-invasive diagnosis technology for bladder cancer, the advantages of urine DNA methylation detection in the diagnosis of bladder cancer, as well as the trend of development for urine non-invasive diagnosis.
